Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Diphtheria

Clinical medicine profile

Diphtheria

Vaccine / immunological product

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
IM / SC / ORAL / ID
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine] Hypersensitivity to the active substances or to any of the excipients, acute severe febrile illness.

Precautions

  • [From component Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine] Temperature of 400C within 48 hours, not due to another identifiable cause, collapse or shock-like state within 48 hours, persistent crying lasting 3 hours, occurring within 48 hours, convulsions with or without fever, occurring within 3 days.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

N/A generally.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

N/A generally.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Vaccine / immunological product).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.

Adverse effects

  • [From component Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine] Pain, redness or swelling at injection site, fever (more than 38C), drowsiness, irritability, unusual crying, feeding problems.
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Diphtheria / Tetanus…Component mechanism (Diphtheria / Tetanus…
Read complete mechanism

Combination product. Component mechanism (Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine): Combination product. Component mechanism (Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine): MOA-ID_37

Onset

Immune response days–weeks

Duration

Months–lifelong (schedule-dependent)

Route

IM / SC / ORAL / ID

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.

Lactation

Most vaccines compatible; live vaccines usually fine for breastfeeding mother.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceUnsourced template; Component monographs (multi-source pipeline); Local active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.